<DOC>
	<DOCNO>NCT01574326</DOCNO>
	<brief_summary>Objective : In hyperphosphatemic pediatric participant chronic kidney disease ( CKD ) - Evaluate safety tolerability sevelamer carbonate - Evaluate efficacy sevelamer carbonate control serum phosphorus</brief_summary>
	<brief_title>An Efficacy Safety Study Sevelamer Carbonate Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease</brief_title>
	<detailed_description>The study divide 3 period : phosphate binder washout Period ; randomize , double-blind , placebo-controlled , Fixed Dose Period ; open-label , sevelamer carbonate Dose Titration Period .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Hyperphosphatemia</mesh_term>
	<mesh_term>Sevelamer</mesh_term>
	<criteria>The participant CKD require dialysis CKD dialysis estimate glomerular filtration rate ( GFR ) &lt; 60 mL/min/1.73 m^2 base central laboratory result . The participant serum phosphorus level great age appropriate upper limit normal base central laboratory result . The participant active dysphagia , swallow disorder predisposition current bowel obstruction , ileus severe gastrointestinal motility disorder ( ) include severe constipation , major gastrointestinal tract surgery . The participant nonrenal case hyperphosphatemia .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Chronic Kidney Disease</keyword>
	<keyword>Pediatric</keyword>
	<keyword>Sevelamer Carbonate</keyword>
	<keyword>Hyperphosphatemia</keyword>
</DOC>